Evoclin Patent Expiration

Evoclin is a drug owned by Mylan Pharmaceuticals Inc. It is protected by 2 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Feb 03, 2024. Details of Evoclin's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7374747 Pharmaceutical foam
Jan, 2024

(5 months ago)

US7141237 Pharmaceutical foam
Feb, 2024

(5 months ago)


Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Evoclin is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Evoclin's family patents as well as insights into ongoing legal events on those patents.

Evoclin's family patents

Evoclin has patent protection in a total of 15 countries. It's US patent count contributes only to 25.8% of its total global patent coverage. 3 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree for Evoclin.

Family Patents

Coming Soon

Patent Strength Analyzer

Will this be useful for you?


Thank you for your response 🥳

Generic Launch

Generic Release Date:

Evoclin's generic launch date based on the expiry of its last outstanding patent is estimated to be Feb 03, 2024 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Evoclin Generics:

Clindamycin Phosphate is the generic name for the brand Evoclin. 41 different companies have already filed for the generic of Evoclin, with Hikma having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Evoclin's generic

How can I launch a generic of Evoclin before its drug patent expiration? :

You can seek FDA approval to launch a generic drug before the expiration of Evoclin's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Evoclin's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Given below are the details of the already filed Para IV certificates on Evoclin -

Strength Submission Date ANDA(s) Filed First applicant approval Last patent expiry 180 day status
0.01 1 31 Mar, 2010 09 Aug, 2026 Eligible

About Evoclin

Evoclin is a drug owned by Mylan Pharmaceuticals Inc. It is used for treating acne vulgaris. Evoclin uses Clindamycin Phosphate as an active ingredient. Evoclin was launched by Mylan in 2004.

Market Authorisation Date:

Evoclin was approved by FDA for market use on 22 October, 2004.

Active Ingredient:

Evoclin uses Clindamycin Phosphate as the active ingredient. Check out other Drugs and Companies using Clindamycin Phosphate ingredient


Evoclin is used for treating acne vulgaris.


Evoclin is available in aerosol, foam form for topical use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
1% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** AEROSOL, FOAM Discontinued TOPICAL